Quest diagnostics aims to close gaps in maternal healthcare with new obstetrics test panel that includes hepatitis c screening

New test panel follows a quest diagnostics health trends® study with the cdc that revealed less than half of pregnant people are screened for hepatitis c as recommended under guidelines secaucus, n.j. , aug. 17, 2022 /prnewswire/ -- quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services, today announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people easily and reliably for hepatitis c (hcv) with other laboratory tests typically ordered during early pregnancy.
DGX Ratings Summary
DGX Quant Ranking